Organon OGN Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Arcoxia | $266M-1.8% | $271M+5.4% | $257M+6.6% | $241M-0.8% | |
| Atozet | $325M-31.4% | $474M-8.7% | $519M+13.6% | $457M-0.2% | |
| Brenzys | $80M+3.9% | $77M+5.5% | $73M-2.7% | $75M+19.0% | |
| Clarinex | $123M-2.4% | $126M-6.7% | $135M+8.0% | $125M+12.6% | |
| Cozaar/Hyzaar | $219M-9.9% | $243M-13.2% | $280M-13.0% | $322M-9.3% | |
| Diprospan | $150M+7.1% | $140M+55.6% | $90M-25.6% | $121M-3.2% | |
| Dulera | $153M-24.6% | $203M+5.2% | $193M+7.2% | $180M-5.3% | |
| Emgality | $174M+62.6% | $107M— | $0— | $0— | |
| Follistim AQ | $265M+11.8% | $237M-9.5% | $262M+14.4% | $229M-3.4% | |
| Fosamax | $143M-5.9% | $152M-4.4% | $159M+4.6% | $152M-13.6% | |
| Ganirelix Acetate Injection | $100M-8.3% | $109M-1.8% | $111M— | —— | |
| Hadlima | $229M+61.3% | $142M+223% | $44M+132% | $19M+46.2% | |
| Jada | $73M+19.7% | $61M+41.9% | $43M— | —— | |
| Marvelon/Mercilon | $127M-5.2% | $134M+0.8% | $133M+19.8% | $111M+13.3% | |
| Nasonex | $263M-4.7% | $276M+3.8% | $266M+2.3% | $260M+26.8% | |
| Nexplanon/Implanon NXT | $921M-4.5% | $964M+16.1% | $830M-0.5% | $834M+8.6% | |
| NuvaRing | $92M-20.0% | $115M-35.0% | $177M-19.2% | $219M+14.7% | |
| Ontruzant | $99M-29.8% | $141M-9.6% | $156M+28.9% | $121M-3.2% | |
| Other Biosimilars | $33M— | —— | $43M— | —— | |
| Other Cardiovascular | $125M-6.0% | $133M-4.3% | $139M-4.8% | $146M-24.0% | |
| Other Non-Opiod Pain, Bone and Dermatology | $300M+2.7% | $292M+5.8% | $276M+1.1% | $273M-5.2% | |
| Other Respiratory | $51M-5.6% | $54M-15.6% | $64M-1.5% | $65M-26.1% | |
| Other | $338M+3.4% | $327M+2.5% | $319M-2.4% | $327M-9.2% | |
| Other | $81M-30.2% | $116M-4.9% | $122M-16.4% | $146M-27.0% | |
| Other Women's Health | $174M+11.5% | $156M+6.1% | $147M+1.4% | $145M-30.0% | |
| Propecia | $119M+7.2% | $111M-10.5% | $124M-0.8% | $125M-8.1% | |
| Proscar | $97M+3.2% | $94M-3.1% | $97M-4.0% | $101M-12.9% | |
| Renflexis | $251M-8.4% | $274M-1.4% | $278M+23.6% | $225M+21.6% | |
| Rosuzet | $24M-51.0% | $49M-30.0% | $70M-1.4% | $71M+4.4% | |
| Singulair | $252M-30.0% | $360M-11.1% | $405M-1.5% | $411M-0.2% | |
| Vtama | $128M+967% | $12M— | $0— | $0— | |
| Vytorin | $100M-7.4% | $108M-16.3% | $129M-0.8% | $130M-20.7% | |
| Zetia | $342M+7.9% | $317M-1.6% | $322M-13.0% | $370M-2.1% | |
| Revenue by Geography | |||||
| Asia Pacific and Japan | $1B-4.9% | $1.05B-6.9% | $1.13B-1.2% | $1.14B-2.6% | |
| China | $829M-2.1% | $847M-2.0% | $864M-5.8% | $917M-1.8% | |
| Europe and Canada | $1.62B-8.2% | $1.76B+5.4% | $1.67B+2.6% | $1.63B-6.4% | |
| Latin America, Middle East, Russia, and Africa | $1.07B+3.8% | $1.03B+7.2% | $965M+8.3% | $891M+5.9% | |
| Other | $92M-31.9% | $135M-12.3% | $154M+0.7% | $153M-33.8% | |
| U.S. | $1.6B+2.0% | $1.57B+6.4% | $1.48B+2.6% | $1.44B+4.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Organon break its business down?
- Organon (OGN) reports revenue by product across 33 parts — Arcoxia, Atozet, Brenzys, Clarinex and Cozaar/Hyzaar. Each is extracted from the segment footnotes and tracked over time.
- Where does Organon's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Organon's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.